3.2.1.209	1-deoxymannojirimycin	10% residual activity at 0.0002 mM	1183	
3.2.1.209	1-deoxymannojirimycin	-	1183	
3.2.1.209	1-deoxymannojirimycin	trimming is inhibited preferentially by 1-deoxymannojirimycin, inhibits hydrolysis of 4-methylumbelliferyl-alpha-D-mannopyranoside	1183	
3.2.1.209	1-deoxymannojirimycin	found in crystal structures of the active site	1183	
3.2.1.209	1-deoxymannojirimycin	DMJ, inhibition of 4-methylumbelliferyl-alpha-D-mannopyranoside hydrolysis	1183	
3.2.1.209	1-deoxymannojirimycin	the enzyme is inhibited preferentially by 1-deoxymannojirimycin	1183	
3.2.1.209	brefeldin A	known inhibitor of vesicle transport, ablated intracellular turnover of the radiolabeled molecules. Plus digestion with potato acid phosphatase implies that phosphorylation of ER mannosidase I is responsible for the altered electrophoretic mobility	5284	
3.2.1.209	Chloroquine	lysosomotrophic amine capable of raising the pH of acidic intracellular compartments, added to the medium with weak inhibition	1439	
3.2.1.209	Chloroquine	lysosomotrophic amine capable of raising the pH of acidic intracellular compartments, effect on the intracellular fate of endogenous mouse ER mannosidase I	1439	
3.2.1.209	Co2+	-	23	
3.2.1.209	Co2+	50% reduction in alpha-mannosidase activity is observed after addition of 3 mM CoCl2	23	
3.2.1.209	cycloheximide	inhibitory effect like kifunensine	1715	
3.2.1.209	D-mannonolactam amidrazone	inhibitor is a mimic of the mannopyranosyl cation and acts as a potent broad spectrum mannosidase inhibitor. It is inactive against processing glucosidases I and II	10626	
3.2.1.209	deoxymannojirimycin	degradation is inhibited by the the mannosidase inhibitor	6174	
3.2.1.209	dithiothreitol	loss of activity with first-order kinetics	45	
3.2.1.209	EDTA	-	21	
3.2.1.209	EDTA	addition of Ca2+ reverses inhibitory effect	21	
3.2.1.209	EDTA	Ca2+ restores	21	
3.2.1.209	EDTA	complete inactivation at 1.7 mM, Ca2+ restores	21	
3.2.1.209	EGTA	complete inhibition at 5 mM	173	
3.2.1.209	EGTA	complete loss of acvtivity at 0.1 mM, Ca2+ restores	173	
3.2.1.209	kifunensine	10% residual activity at 0.0002 mM	1980	
3.2.1.209	kifunensine	50% inhibition at 0.0001 mM	1980	
3.2.1.209	kifunensine	inhibits Golgi alpha1,2-mannosidase. Addition of kifunensine completely inhibits mannose trimming from alpha1-antitrypsin null (Hong Kong) in mock transfected cells. Kifunensine inhibits alpha1-antitrypsin null (Hong Kong) degradation in cells co-transfected with the Golgi mannosidases	1980	
3.2.1.209	kifunensine	inhibits Golgi alpha1,2-mannosidase. Addition of kifunensine completely inhibits mannose trimming from alpha1-antitrypsin null (Hong Kong) in mock transfected cells. Kifunensine inhibits alpha1-antitrypsin null (Hong Kong)degradation in cells co-transfected with the Golgi mannosidases; inhibits Golgi alpha1,2-mannosidase. Addition of kifunensine completely inhibits mannose trimming from alpha1-antitrypsin null (Hong Kong) in mock transfected cells. Kifunensine inhibits alpha1-antitrypsin null (Hong Kong)degradation in cells co-transfected with the Golgi mannosidases	1980	
3.2.1.209	kifunensine	found in crystal structures of the active site	1980	
3.2.1.209	kifunensine	general membrane-permeable inhibitor of alpha-mannosidase activity	1980	
3.2.1.209	kifunensine	general membrane-permeable inhibitor of alpha-mannosidase activity, effect on the intracellular fate of endogenous mouse ER mannosidase I	1980	
3.2.1.209	kifunensine	-	1980	
3.2.1.209	kifunensine	degradation is inhibited by the the mannosidase inhibitor	1980	
3.2.1.209	lactacystin	irreversible inhibitor of multicatalytic proteasomes, only a minor effect on the disappearance of radiolabeled human ER mannosidase I	2107	
3.2.1.209	lactacystin	irreversible inhibitor of multicatalytic proteasomes, effect on the intracellular fate of endogenous mouse ER mannosidase I	2107	
3.2.1.209	leupeptin	lysosomal protease inhibitor, intracellular turnover of pulse-radiolabeled recombinant human ER mannosidase I is substantially inhibited	217	
3.2.1.209	leupeptin	lysosomal protease inhibitor, effect on the intracellular fate of endogenous mouse ER mannosidase I	217	
3.2.1.209	Mg2+	-	6	
3.2.1.209	Mn2+	-	11	
3.2.1.209	additional information	no inhibition by swainsonine	2	
3.2.1.209	additional information	staurosporine and genistein have an effect, tesing arrested intracellular turnover in response to selective inhibition of serine kinase activity	2	
3.2.1.209	additional information	shift in migration is due to mannose trimming. Effects are not observed with the class II mannosidase inhibitor swainsonine	2	
3.2.1.209	additional information	not affected by EDTA	2	
3.2.1.209	additional information	not inhibitory: swainsonine	2	
3.2.1.209	N-carbobenzoxyl-leucinyl-leucinyl-leucinal	degradation is inhibited by the proteasomal inhibitor	138829	
3.2.1.209	pepstatin A	in the presence of mixed membrane fraction from strain ATTC 26555, the 52 kDa polypeptide is converted into a 43 kDa active product. Protease inhibitors, such as phenylmethylsulphonylfluoride, trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane and 1,10-phenantroline, fail to prevent proteolysis. Pepstatin A, an aspartyl protease inhibitor, fully blocked enzyme processing	309	
3.2.1.209	swainsonine	inhibits hydrolysis of 4-methylumbelliferyl-alpha-D-mannopyranoside	646	
3.2.1.209	swainsonine	SW, inhibition of 4-methylumbelliferyl-alpha-D-mannopyranoside hydrolysis	646	
3.2.1.209	swainsonine	-	646	
3.2.1.209	Zn2+	-	14	
3.2.1.209	Zn2+	50% reduction in alpha-mannosidase activity is observed after addition of 3 mM ZnCl2	14